Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / COM
-
Number of holders
-
314
-
Total 13F shares, excl. options
-
58.2M
-
Shares change
-
-2.28M
-
Total reported value, excl. options
-
$8.41B
-
Value change
-
-$184M
-
Put/Call ratio
-
0.44
-
Number of buys
-
190
-
Number of sells
-
-171
-
Price
-
$145.71
Significant Holders of Biohaven Pharmactl Hldg Co L - COM (BHVN) as of Q2 2022
412 filings reported holding BHVN - Biohaven Pharmactl Hldg Co L - COM as of Q2 2022.
Biohaven Pharmactl Hldg Co L - COM (BHVN) has 314 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 58.2M shares
.
Largest 10 shareholders include BlackRock Inc. (5.07M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.04M shares), Capital World Investors (2.64M shares), FARALLON CAPITAL MANAGEMENT LLC (1.95M shares), UBS OCONNOR LLC (1.94M shares), MARSHALL WACE, LLP (1.93M shares), STATE STREET CORP (1.75M shares), Capital International Investors (1.53M shares), VANGUARD GROUP INC (1.43M shares), and Pentwater Capital Management LP (1.43M shares).
This table shows the top 314 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.